



IN THE CLAIMS

1-71. (Cancelled)

72. (Withdrawn) A method for treating cancer of the bladder comprising:
contacting the luminal surface of the bladder with a pretreatment composition comprising
a transduction enhancing agent; and
subsequently contacting the luminal surface of the bladder with a composition
comprising an oncolytic virus;
wherein the transduction enhancing agent has the following general formula (I) or the
following general formula


(II):



wherein X is a sulfur or

c oxygen atom, each R² is independently

hydrogen or a moiety represented by:




and R¹ represents an alkyl or alkenyl group; and

wherein the luminal surface of the bladder is contacted with the pretreatment composition
for at least 10 minutes.

73. (Withdrawn) The method of Claim 72, wherein R¹ comprises at least 12 carbon atoms.

74. (Withdrawn) The method of Claim 72, wherein each R² is hydrogen.

75. (Withdrawn) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:



wherein n is a positive integer.

76. (Withdrawn) The method of Claim 75, wherein n is 11 or greater.

77. (Withdrawn) The method of Claim 75, wherein n is 11.


78. (Withdrawn) The method of Claim 77, wherein the pretreating composition comprises about 0.025 to about 0.4 % by weight of the transduction enhancing agent.

79. (Withdrawn) The method of Claim 72, wherein the luminal surface of the bladder is contacted with the pretreatment composition for at least 20 minutes.

80. (Withdrawn) The method of Claim 79, wherein the luminal surface of the bladder is contacted with the composition comprising the oncolytic virus for 15 minutes or less.

81. (Withdrawn) The method of Claim 79, wherein the luminal surface of the bladder is contacted with the composition comprising the oncolytic virus for 10 minutes or less.

82. (Withdrawn) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:




wherein n is a positive integer.

83. (Withdrawn) The method of Claim 72, wherein the oncolytic adenovirus.

84. (Withdrawn) The method of Claim 83, wherein the oncolytic adenovirus is CG8840.

85. (Withdrawn) The method of Claim 72, wherein the oncolytic virus composition comprises at least 4×10^{10} viral particles.


86. (Withdrawn) The method of Claim 72, wherein the transduction enhancing agent has the chemical formula:



where R^1 represents

an alkyl or alkenyl group.

87. (Withdrawn) The method of Claim 86, wherein R^1 is represented by:




88-95. (Cancelled)


96. (New) A method for treating cancer of the bladder comprising:
contacting the luminal surface of the bladder with a pretreatment composition comprising a transduction enhancing agent effective to increase transduction in the bladder epithelium; and subsequently contacting the luminal surface of the bladder with a composition comprising an oncolytic adenovirus; wherein the transduction enhancing agent is a disaccharide having a lipophilic substituent, and wherein said oncolytic adenovirus exhibits preferential expression in the bladder epithelium to a greater extent when said transduction enhancing agent is present in said pretreatment composition than when said transduction enhancing agent is not present.

97. (New) The method of Claim 96, wherein the transduction enhancing agent is a disaccharide having a lipophilic substituent and wherein the disaccharide is selected from the group consisting of sucrose, lactose, maltose, isomaltose, trehalose and cellobiose.


98. (New) The method of Claim 96, wherein the transduction enhancing agent has the following general formula (I)




wherein X is a sulfur or oxygen atom, each R² is independently hydrogen or a moiety represented by:



and R¹ represents an alkyl or alkenyl group.



99. (New) The method of Claim 96, wherein the transduction enhancing agent has the chemical formula:



wherein n is from 11 to 14 and wherein the number 1 carbon of the right-hand monosaccharide is in the alpha or beta configuration.

100. (New) The method of Claim 99, wherein n is 11.


101. (New) The method of Claim 96, wherein the pretreating composition comprises about 0.02 to about 0.5% by weight of the transduction enhancing agent.

102. (New) The method of Claim 101, wherein the pretreatment composition comprises about 0.05% by weight of the transduction enhancing agent.

103. (New) The method of Claim 99, wherein the pretreating composition comprises about 0.02 to about 0.5% by weight of the transduction enhancing agent.

104. (New) The method of Claim 103, wherein the pretreatment composition comprises about 0.05% by weight of the transduction enhancing agent.

105. (New) The method of Claim 96, wherein the transduction enhancing agent has the chemical formula:



wherein n is from 1 to 14 and wherein the number 1 carbon of the right-hand monosaccharide is in the alpha or beta configuration.

106. (New) The method of Claim 105, wherein n is 6.

107. (New) The method of Claim 105, wherein the pretreating composition comprises about 0.02 to about 0.5% by weight of the transduction enhancing agent.

108. (New) The method of Claim 107, wherein the pretreatment composition comprises about 0.1% by weight of the transduction enhancing agent.

109. (New) The method of Claim 96, wherein the oncolytic adenovirus is CG8840.

110. (New) The method of Claim 96, wherein the oncolytic virus composition further comprises a chemotherapeutic agent.

111. (New) The method of Claim 110, wherein the chemotherapeutic agent is docetaxel.

112. (New) The method of Claim 96, wherein contacting the luminal surface of the bladder with a pretreatment composition comprises delivering the pretreatment composition to the bladder by instillation.

113. (New) The method of Claim 96, further comprising washing the luminal surface of the bladder after contact with the pretreatment composition and before contact with the oncolytic virus composition.

114. (New) The method of Claim 96, wherein contacting the luminal surface of the bladder with a composition comprising an oncolytic virus comprises delivering about 50 to about 500 ml of the oncolytic virus composition to the bladder by instillation.

115. (New) The method of Claim 96, wherein the oncolytic virus composition comprises from about 1×10^{11} to about 1×10^{14} viral particles.

116. (New) The method of Claim 112, wherein the pretreatment composition is contacted with the luminal surface of the bladder for about 5 minutes.
117. (New) The method of Claim 96, wherein the pretreatment composition further comprises an oxidizing agent.
118. (New) The method of Claim 117, wherein the oxidizing agent is selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid.
119. (New) The method of Claim 96, wherein the lipophilic substituent comprises an alkane group.
120. (New) The method of Claim 96, wherein the lipophilic substituent is an alkanoic acid residue.
121. (New) The method of Claim 99, wherein the oncolytic adenovirus is CG8840.
122. (New) The method of Claim 99, wherein the oncolytic virus composition further comprises a chemotherapeutic agent.
123. (New) The method of Claim 122, wherein the chemotherapeutic agent is docetaxel.
124. (New) The method of Claim 99, wherein contacting the luminal surface of the bladder with a pretreatment composition comprises delivering the pretreatment composition to the bladder by instillation.
125. (New) The method of Claim 99, further comprising washing the luminal surface of the bladder after contact with the pretreatment composition and before contact with the oncolytic virus composition.
126. (New) The method of Claim 99, wherein contacting the luminal surface of the bladder with a composition comprising an oncolytic virus comprises delivering about 50 to about 500 ml of the oncolytic virus composition to the bladder by instillation.

127. (New) The method of Claim 99, wherein the oncolytic virus composition comprises from about 1×10^{11} to about 1×10^{14} viral particles.

128. (New) The method of Claim 124, wherein the pretreatment composition is contacted with the luminal surface of the bladder for about 5 minutes.


129. (New) The method of Claim 99, wherein the pretreatment composition further comprises an oxidizing agent.

130. (New) The method of Claim 129, wherein the oxidizing agent is selected from the group consisting of hypochlorous acid, hydrogen peroxide, and peroxyacetic acid.

131. (New) The method of Claim 99, wherein the lipophilic substituent comprises an alkane group.

132. (New) The method of Claim 99, wherein the lipophilic substituent is an alkanoic acid residue.

133. (New) The method of Claim 96, wherein the transduction enhancing agent has the chemical formula:



where R^1 represents an alkyl or alkenyl group.

134. (New) The method of Claim 133, wherein R^1 is represented by:

